Stay updated with breaking news from Special Protocol Assessment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy...
The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical...
First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of cellular...
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with...